24-week Phase 2b IMPAHCT trial of AV-101 for pulmonary arterial hypertension does not meet primary endpoint, but is well tolerated and Phase 2b/3 trial continues.
Aerovate Therapeutics announces 24-week topline results from Phase 2b portion of IMPAHCT trial, a study of AV-101, a dry powder inhaled formulation of imatinib, for pulmonary arterial hypertension. The study did not meet its primary endpoint for improvement in pulmonary vascular resistance compared to placebo for any of the studied doses, but AV-101 was well tolerated. The Phase 2b/Phase 3 trial is ongoing.
June 17, 2024
3 Articles